One-year evaluation of the safety and efficacy of ipratropium bromide HFA and CFC inhalation aerosols in patients with chronic obstructive pulmonary disease

Clinical Drug Investigation

Volumn 23, Issue 3, 2003, Pages 181-191

  Brazinsky, Shari A ^a   Lapidus, Robert J ^b   Weiss, Laurence A ^c   Ghafouri, Mo ^d   Fagan, Nora M ^d   Witek, Theodore J ^d   Amgott, Theodore ^e   Arcuri, Peter A ^e   Benkert, Robert ^e   Brannen, Alfred Lynne ^e   Flesher, Jonathan ^e   Gilliard, Lawrence M ^e   Hendrickson, Roman M ^e   Hoyt, James D ^e   Imes, Norman K ^e   Jacobson, Kirk ^e   Kaye, Mitchell G ^e   Koeppl, Christopher ^e   Lafata, John ^e   Laviolette, Judy D ^e   Macy, Charles ^e   Mirani, Mahendra ^e   Morin, David ^e   Morganroth, Melvin L ^e   Pogue, Bryan C ^e   Rick, James H ^e   Rudolph, Lance A ^e   Schelbar, E Joseph ^e   Sherman, Bruce W ^e   Strohl, Kingman Perkins ^e   Tangel, Douglas Joaquim ^e   Verdegem, Thomas D ^e   Young, Douglas ^e   more..

^a Inst of Healthcare Assessment Inc   (United States)

^b Rocky Mountain Pulmonary Medicine   (United States)

^c Pulmonary Department   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e Boehringer Ingelheim Pharmaceut I ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; IPRATROPIUM BROMIDE;

ADULT; AEROSOL; AGED; AIRWAY OBSTRUCTION; ARTICLE; BACKACHE; BRONCHITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LONG TERM CARE; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PAIN; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SHORT COURSE THERAPY; SINUSITIS; URINARY TRACT INFECTION;

EID: 0037232258     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323030-00004     Document Type: Article

References (33)

1. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328: 1017-22
2. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974; 249: 810-2
3. Montreal Protocol. The Montreal Protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP, 1987). Fed Reg 1994; 59: 56276-98
4. Dolovich M. New delivery systems and propellants. Can Respir J 1999; 6: 290-5
5. United Nations Environment Programme Technology and Economic Assessment Panel of the Montreal Protocol on substances that deplete the ozone layer. April 1997 Report Volume I. TEAP 1997
6. Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to VENTOLIN® over 12 weeks of regular use in asthmatics. Chest 1998; 113: 283-9
7. Dahl R, Ringdal N, Ward SM, et al. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC beclomethasone dipropionate. Br J Clin Pract 1997; 51: 11-5
8. Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriation comparable to proventil and ventolin. Ann Allergy Asthma Immunol 1997; 79: 85-8
9. Donnell D, Harrison LI, Ward S, et al. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Eur J Clin Pharmacol 1995; 48: 473-7
10. Harrison LI, Donnell D, Simmons JL, et al. Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects. J Pharm Pharmacol 1996; 48: 596-600
11. Hayman G. Why the environment matters. Br J Clin Pract 1995; 49 Suppl. 79: 2-6
12. Tinkelman DG, Bleecker ER, Ramsdell J, et al. Proventil HFA and VENTOLIN® have similar safety profiles during regular use. Chest 1998; 113: 290-6
13. Anon. CPMP on possible alternatives to CFCs. Scrip 1994; 1943: 26
14. Friedman M, Littner M, Ghafouri M, et al. Ipratropium bromide HFA MDI42 μg is clinically comparable to ipratropium bromide CFC MDI 42 μg in the treatment of COPD [abstract]. Am J Respir Crit Care Med 2001; 163 (5): A278
15. Cuvelier A, Iacono P, Guemas E, et al. Ipratropium bromide MDI containing HFA propellant is as safe and effective as the CFC formulation: a dose confirmation study in patients with COPD [abstract]. Am J Respir Crit Care Med 1998; 157 (3): A800
16. Wedzicha JA, Towse LJ, Jirou-Najou J-L. Therapeutic equivalence of ipratropium bromide MDIs formulated with HFA or CFC propellants in long-term treatment of COPD [abstract]. Eur Respir J 1997; 10 Suppl. 25: 427s
17. Taylor J, Kotch A, Rice K, et al., and the Ipratropium Bromide HFA Study Group. Ipratropium bromide HFA inhalation aerosol is safe and effective in patients with chronic obstructive pulmonary disease (COPD). Chest 2001; 120: 1253-61
18. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-6
19. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995; 152: S77-S120
20. Morris JF, Koski A, Temple WP, et al. Fifteen-year interval spirometric evaluation of the Oregon predictive equations. Chest 1988; 93: 123-7
21. American Thoracic Society. Standardization of Spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36
22. Federal Drug agency (FDA), Centre for Drug Evaluation and Research, Division of Oncology and Pulmonary Drug Products. Guidance document: points to consider: clinical development programs for MDI and DPI drug products. 1994 Sep: 19
23. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-420
24. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) executive summary. Respir Care 2001; 46: 798-825
25. Goldberg J, Bohning W, Schmidt P, et al. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison. Respir Med 2000; 94: 948-53
26. Huchon G, Hofbauer P, Cannizzaro G, et al. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J 2000; 15: 663-9
27. Maesen FP, Greefhorst LP, Smeets JJ, et al. Therapeutic equivalence of a novel HFA 134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide: a randomized double-blind placebo-controlled crossover study in patients with asthma. Respiration 1997; 64: 273-80
28. Furukawa C, Atkinson D, Forster TJ, et al. Controlled trial of two formulations of cromolyn sodium in the treatment of asthmatic patients ≥12 years of age. Chest 1999; 116: 65-72
29. Blumenthal MN, Casale TB, Fink JN, et al. Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial. J Allery Clin Immunol 1998; 101: 7-13
30. Perruchoud AP, Lundback B, Yigla M, et al. Clinical efficacy and safety of fluticasone propionate 1mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International Study Group. Respir Med 2000: 94 Suppl B: S35-41
31. Nelson HS, Kane RE, Petillo J, et al. Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. Azmacort HFA Study Group. J Asthma 2000; 37: 145-52
32. Ramsdell JW, Klinger NM, Ekholm BP, et al. Safety of longterm treatment with HFA albuterol. Chest 1999; 115: 945-51
33. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22